The Wall Street Journal reports vaccine makers promise to not seek regulatory approval until there is evidence their SARS-CoV-2 vaccines are safe and effective.
The collaborators aim to develop lung cancer molecular diagnostic tests using molecular, clinical, and imaging-based artificial intelligence technologies.
The companies initially plan to validate biomarkers for use with the Oncomine Dx Target Test to identify NSCLC patients for enrollment into clinical trials.
Howard Hughes Medical Institute will be requiring its researchers to publish their work so it is immediately accessible to the public, ScienceInsider writes.
About 150 million rapid coronavirus tests purchased by the US federal government are to be distributed to nursing homes, colleges, and the states, according to the New York Times.
